ArticleBioData mining2026
Multimodal deep learning for survival prediction and biomarker discovery in non-small cell lung cancer.
Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDeep learning (DL) is revolutionizing high-dimensional analysis for clinical applications, with multimodal approaches showing promise in integrating diverse datasets and improving predictive accuracy. However, its use in prognostic assessment, particularly for non-small-cell lung cancer (NSCLC), remains limited.
methodsWhole-slide imaging (WSI), next-generation sequencing (NGS), and clinical features from 2,366 NSCLC patients sourced from various databases were analyzed. A Sequential-Adapted Attention (SeAttn) model was developed to process WSI, while multiple DL models analyzed genetic and clinical data. Multimodal features were combined using a COX-based DL approach to predict long-term prognosis. Validation (N = 100) and test (N = 101) cohorts were used to confirm model performance.
resultsThe SeAttn model achieved an area under the curve (AUC) of 0.98 for NSCLC histologic subtype prediction in the test cohort (P < 0.0001). Individually, WSI, clinical, and genetic features predicted prognosis with concordance indices (C-indices) of 0.55–0.67 using the test cohort. Combined multimodal features improved the test cohort C-index to 0.71 (P = 0.002). The model accurately predicted prognosis up to 5 years post-diagnosis (P < 0.05 for all time-dependent AUCs) and stratified patients by overall survival (P = 0.012). SeAttn demonstrated attention shifts when comparing subtyping and prognosis models and revealed immuno-hot and immuno-cold stroma enrichment underlying survival differences. Novel prognostic markers, including TPTE mutation, microRNA cluster amplification, and RIPK4-IL10RB co-deletion, were identified and validated.
conclusionsThis multimodal DL framework demonstrates robust prognostic capabilities for NSCLC, integrating clinical, genetic, and imaging data to yield accurate survival estimates and identify biomarkers. These findings highlight the scalability of multimodal DL for broader cancer applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.